{
 "blind": false,
 "comparisons": 257,
 "eligible_trials": 234,
 "exclusions": {
  "active_comparator_only": 102,
  "background_differs": 2,
  "glp1_combined_with_other_active": 3,
  "glp1_is_background": 9,
  "groups_not_randomized_arms": 10,
  "no_glp1_group": 2,
  "no_placebo_group": 69,
  "other": 1
 },
 "found": 539,
 "glp1_participants": 93765,
 "half1_trials": 117,
 "half2_trials": 117,
 "overcount_factor": 2.05718,
 "participants": 161309,
 "participants_by_molecule": {
  "albiglutide": 11467,
  "cotadutide": 1469,
  "danuglipron": 1245,
  "dulaglutide": 15006,
  "efinopegdutide": 355,
  "efpeglenatide": 5161,
  "exenatide": 18020,
  "liraglutide": 25904,
  "lixisenatide": 10921,
  "mazdutide": 177,
  "orforglipron": 6834,
  "retatrutide": 618,
  "semaglutide": 58029,
  "survodutide": 1040,
  "tirzepatide": 9018
 },
 "participants_by_population": {
  "mixed": 725,
  "other": 5015,
  "overweight_obesity": 42927,
  "type1_diabetes": 3011,
  "type2_diabetes": 109631
 },
 "placebo_participants": 67544,
 "screened": 432,
 "structural_exclusions": {
  "design_crossover": 40,
  "design_sequential": 6,
  "design_single_group": 4,
  "fewer_than_two_adverse_event_groups": 1,
  "not_randomized": 56
 }
}